.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 8,569,325

« Back to Dashboard

Claims for Patent: 8,569,325

Title:Method of treatment with coadministration of aspirin and prasugrel
Abstract: A method for the prevention of diseases caused by thrombus or embolus. The method is to separately administer 2-acetoxy-5-(.alpha.-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahyd- rothieno[3,2-c]pyridine or a pharmaceutically acceptable salt thereof, and aspirin, in their pharmacologically effective amounts, to a warm-blooded animal.
Inventor(s): Asai; Fumitoshi (Nishitokyo, JP), Sugidachi; Atsuhiro (Kawasaki, JP), Ogawa; Taketoshi (Tokyo, JP), Inoue; Teruhiko (Ube, JP)
Assignee: Daiichi Sankyo Company, Limited (Tokyo, JP) Ube Industries, Ltd. (Yamaguchi, JP)
Application Number:12/006,546
Patent Claims: 1. A method for preventing disease caused by thrombus or embolus, said method consisting of separately administering to a human in need of prevention of said disease: (a) 2-acetoxy-5 -(.alpha.-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6 ,7-tetrahydrothieno[3,2-c]pyridine or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients, lubricants, binders, disintegrators, emulsifiers, stabilizers, corrigents and/or diluents, and (b) aspirin, and one or more pharmaceutically acceptable excipients, lubricants, binders, disintegrators, emulsifiers, stabilizers, corrigents and/or diluents, wherein said 2-acetoxy-5 -(.alpha.-cyclopropylcarbonyl-2-fluorobenzyl)-4,5 ,6,7-tetrahydrothieno[3,2-c]pyridine or the pharmaceutically acceptable salt thereof, and aspirin are administered in pharmacologically effective amounts to prevent said disease caused by thrombus or embolus by reducing thrombogenesis or by reducing platelet aggregation in said human, after both (a) and (b) have been administered.

2. The method according to claim 1, wherein the pharmaceutically acceptable salt is 2-acetoxy-5-(.alpha.-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahyd- rothieno[3,2-c]pyridine hydrochloride.

3. A method for treating a disease caused by thrombus or embolus, said method consisting of separately administering to a human in need of reduction of thrombogenesis or reduction of platelet aggregation: (a) 2-acetoxy-5 -(.alpha.-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,- 2-c]pyridine or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients, lubricants, binders, disintegrators, emulsifiers, stabilizers, corrigents and/or diluents, and (b) aspirin, and one or more pharmaceutically acceptable excipients, lubricants, binders, disintegrators, emulsifiers, stabilizers, corrigents and/or diluents, wherein said 2-acetoxy-5 -(.alpha.-cyclopropylcarbonyl-2-fluorobenzyl)-4,5 ,6,7-tetrahydrothieno[3,2-c]pyridine or the pharmaceutically acceptable salt thereof, and aspirin are administered in pharmacologically effective amounts to treat said disease caused by thrombus or embolus by reducing thrombogenesis or by reducing platelet aggregation in said human, after both (a) and (b) have been administered.

4. The method according to claim 1, wherein said disease caused by thrombus or embolus is a cardiovascular or cerebrovascular disorder.

5. The method according to claim 1, wherein said disease caused by thrombus or embolus is thromboembolism associated with atherosclerosis or diabetes mellitus.

6. The method according to claim 1, wherein said disease caused by thrombus or embolus are unstable angina pectoris, cerebral ischemic insult or restenosis due to angioplasty, endarterectomy or stent therapy.

7. The method according to claim 3, wherein the pharmaceutically acceptable salt is 2-acetoxy-5-(.alpha.-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahyd- rothieno[3,2-c]pyridine hydrochloride.

8. A method for treating a patient undergoing stenting or angioplasty consisting of separately administering to said patient: (a) 2-acetoxy-5 -(.alpha.-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3 ,2-c]pyridine or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients, lubricants, binders, disintegrators, emulsifiers, stabilizers, corrigents and/or diluents, and (b) aspirin, and one or more pharmaceutically acceptable excipients, lubricants, binders, disintegrators, emulsifiers, stabilizers, corrigents and/or diluents, wherein said 2-acetoxy-5 -(.alpha.-cyclopropylcarbonyl-2-fluorobenzyl)-4,5 ,6,7-tetrahydrothieno[3,2-c]pyridine or the pharmaceutically acceptable salt thereof, and aspirin are administered in pharmacologically effective amounts to reduce the incidence or severity of restenosis in said patient undergoing stenting or angioplasty, after both (a) and (b) have been administered.

9. The method according to claim 8, wherein the pharmaceutically acceptable salt is 2-acetoxy-5-(.alpha.-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahyd- rothieno[3 ,2-c]pyridine hydrochloride.

10. The method according to claim 2, wherein the 2-acetoxy-5-(.alpha.-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahyd- rothieno[3 ,2-c]pyridine hydrochloride, and aspirin are administered at separate times.

11. The method according to claim 1, wherein the pharmacologically effective amounts are pharmacologically effective amounts for said 2-acetoxy-5-(.alpha.-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahyd- rothieno[3 ,2-c]pyridine hydrochloride and aspirin, individually.

12. The method according to claim 3, wherein said disease caused by thrombus or embolus is a cardiovascular disorder.

13. The method according to claim 3, wherein said disease caused by thrombus or embolus is thromboembolism associated with atherosclerosis or diabetes mellitus.

14. The method according to claim 3, wherein said diseases caused by thrombus or embolus are unstable angina pectoris, or restenosis due to angioplasty, endarterectomy or stent therapy.

15. A method for reducing event rate of diseases caused by thrombus or embolus, said method consisting of separately administering to a human in need of reduction of said event rate of said diseases: (a) 2-acetoxy-5 -(.alpha.-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3 ,2-c]pyridine or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients, lubricants, binders, disintegrators, emulsifiers, stabilizers, corrigents and/or diluents, and (b) aspirin, and one or more pharmaceutically acceptable excipients, lubricants, binders, disintegrators, emulsifiers, stabilizers, corrigents and/or diluents, wherein said 2-acetoxy-5 -(.alpha.-cyclopropylcarbonyl-2-fluorobenzyl)-4,5 ,6,7-tetrahydrothieno[3,2-c]pyridine or the pharmaceutically acceptable salt thereof, and aspirin are administered in pharmacologically effective amounts to said reduce event rate of said diseases caused by thrombus or embolus by reducing thrombogenesis or by reducing platelet aggregation in said human, after both (a) and (b) have been administered.

16. The method according to claim 15, wherein the pharmaceutically acceptable salt is 2-acetoxy-5-(.alpha.-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahyd- rothieno[3 ,2-c]pyridine hydrochloride.

17. The method according to claim 15, wherein said diseases caused by thrombus or embolus are selected from the group consisting of: diseases induced by platelet aggregation, cardiovascular disorders, cerebrovascular disorders, and thromboembolism caused by thromboembolization.

18. The method according to claim 15, wherein said diseases caused by thrombus or embolus are selected from the group consisting of: stable or unstable angina pectoris, thromboembolism associated with atherosclerosis or diabetes mellitus, recurrent embolism after degradation of original thrombus, embolism, ischemia-induced dementia, peripheral arteriopathy, thromboembolization associated with hemodialysis or atrial fibrillation, and thromboembolization in vascular prosthesis or in bypass between the aorta and the coronary artery.

19. The method according to claim 15, wherein said diseases caused by thrombus or embolus are diseases selected from the group consisting of stable or unstable angina pectoris, cerebral ischemic insult, and restenosis due to angioplasty, endarterectomy or stent therapy.

20. A method for reducing thrombotic cardiovascular or thrombotic cerebrovascular events in a human in need of reduction of said events, said method consisting of separately administering: (a) 2-acetoxy-5-(.alpha.-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahyd- rothieno[3,2-c]pyridine or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients, lubricants, binders, disintegrators, emulsifiers, stabilizers, corrigents and/or diluents, and (b) aspirin, one or more pharmaceutically acceptable excipients, lubricants, binders, disintegrators, emulsifiers, stabilizers, corrigents and/or diluents, wherein said 2-acetoxy-5-(.alpha.-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahyd- rothieno[3,2-c]pyridine or the pharmaceutically acceptable salt thereof, and aspirin are administered in pharmacologically effective amounts to reduce thrombotic cardiovascular or thrombotic cerebrovascular events by reducing thrombogenesis or by reducing platelet aggregation in said human, after both (a) and (b) have been administered.

21. The method according to claim 20, wherein the pharmaceutically acceptable salt is 2-acetoxy-5-(.alpha.-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahyd- rothieno[3 ,2-c]pyridine hydrochloride.

22. The method according to claim 20, wherein said method reduces thrombotic cardiovascular events in said human.

23. The method according to claim 20, wherein said method reduces thrombotic cerebrovascular events in said human.

24. A method for reducing thrombogenesis or reducing platelet aggregation in a human, said method consisting of separately administering to said human: (a) 2-acetoxy-5-(.alpha.-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahyd- rothieno[3 ,2-c]pyridine or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients, lubricants, binders, disintegrators, emulsifiers, stabilizers, corrigents and/or diluents, and (b) aspirin, and one or more pharmaceutically acceptable excipients, lubricants, binders, disintegrators, emulsifiers, stabilizers, corrigents and/or diluents, wherein said 2-acetoxy-5-(.alpha.-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahyd- rothieno[3,2-c]pyridine or the pharmaceutically acceptable salt thereof, and aspirin are administered in pharmacologically effective amounts to reduce thrombogenesis or reduce platelet aggregation in said human, after both (a) and (b) have been administered.

25. The method according to claim 24, wherein the pharmaceutically acceptable salt is 2-acetoxy-5-(.alpha.-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahyd- rothieno[3 ,2-c]pyridine hydrochloride.

26. The method according to claim 25, wherein the 2-acetoxy-5-(.alpha.-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahyd- rothieno[3 ,2-c]pyridine hydrochloride, and aspirin are administered at separate times.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc